Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK7 | Q13164 | 3/20 | 0.47 |
| ▸ | KIT | P10721 | 7/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25232266 | 1.00 | MAPK7 (0.47) | MAPK7KITMTNR1BEPHX2MAP4K4 | |
| SCHEMBL19032267 | 0.92 | MAPK7 (0.47) | MAPK7KITMTNR1BMAP4K4 | |
| SCHEMBL19049680 | 0.89 | MAPK7 (0.58) | MAPK7KITMTNR1BMAP4K4 | |
| SCHEMBL25423050 | 0.88 | MAPK7 (0.48) | MAPK7KITMTNR1BEPHX2 | |
| SCHEMBL30406045 | 0.86 | MAPK7 (0.44) | MAPK7KITMTNR1BEPHX2 | |
| SCHEMBL30405762 | 0.85 | HTT (0.49) | KITMAP4K4GPR119HDAC1HDAC2 | |
| SCHEMBL25422069 | 0.85 | HTT (0.49) | KITMAP4K4GPR119HDAC1HDAC2 | |
| SCHEMBL25280892 | 0.85 | KIT (0.44) | KITMAP4K4GPR119HDAC1HDAC2 | |
| SCHEMBL30405237 | 0.85 | KIT (0.44) | KITMAP4K4GPR119HDAC1HDAC2 | |
| SCHEMBL30406162 | 0.83 | KIT (0.52) | KITMAP4K4CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163061-A1 | INHIBITORS OF MENIN-MLL INTERACTION | BALA THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| EP-4444300-A2 | INHIBITORS OF MENIN-MLL INTERACTION | Bala Therapeutics, Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| CN-118647378-A | Inhibitors of Mei Nen protein interaction with MLL | 巴拉疗法公司 | 2024-09-13 | — | — | CN | disclosed |
| WO-2023107696-A2 | INHIBITORS OF MENIN-MLL INTERACTION | BALA THERAPEUTICS, INC. (US) | 2023-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163061-A1 | INHIBITORS OF MENIN-MLL INTERACTION | MLLT1, MEN1, BMI1 | MAPK7 789/4885KIT 1067/4885MTNR1B 558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.